Corvus Pharmaceuticals, Inc. Common Stock (CRVS) Stock
NASDAQ · CRVS
Key stats
- Market cap
- $967.53M
- Price / Earnings ratio
- -14.9x
- EPS (TTM)
- -$0.71
- Volume
- Loading
- 52-week high
- $26.95
- 52-week low
- $6.39
Source: third-party data provider, as of November 13, 2026
Compare with CRVS
Recent news

MarketBeat
Corvus Pharmaceuticals Q2 Earnings Call Highlights
CRVSAugust 7, 2026
MarketBeat
Corvus Pharmaceuticals Q2 Earnings Call Highlights
CRVS

The Motley Fool
Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy?
CRVSJune 23, 2026
The Motley Fool
Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy?
CRVS

Stocktwits
CRVS Stock Surges 10%, Hits 50-DMA For First Time In A Month – Here’s Why Goldman Sachs Sees A 166% Upside
CRVSApril 17, 2026
Stocktwits
CRVS Stock Surges 10%, Hits 50-DMA For First Time In A Month – Here’s Why Goldman Sachs Sees A 166% Upside
CRVS

MarketBeat
Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026
CRVSFebruary 2, 2026
MarketBeat
Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026
CRVS
Technical indicators
- RSI 14
- 58.15
- MACD 12/26/9
- -0.03
- EMA 9 of MACD
- -0.27
- MACD histogram
- 0.25
- SMA 50
- $11.33
- Price above SMA 50
- EMA 50
- $11.28
- Price above EMA 50
- SMA 200
- $14.09
- Price below SMA 200
- EMA 200
- $12.70
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
Revenue
Net income
Net margin %
2021
2022
2023
2024
2025
0000
Debt & Balance Sheet
Total assets
Total liabilities
2021
2022
2023
2024
2025
131M87M43M0
Revenue to Profit
2025$0.0
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-15.3M
Net incomeEarnings
No data available
Source: third-party data provider
Latest news

MarketBeat
Corvus Pharmaceuticals Q2 Earnings Call Highlights
CRVSAugust 7, 2026
MarketBeat
Corvus Pharmaceuticals Q2 Earnings Call Highlights
CRVS

The Motley Fool
Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy?
CRVSJune 23, 2026
The Motley Fool
Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy?
CRVS

Stocktwits
CRVS Stock Surges 10%, Hits 50-DMA For First Time In A Month – Here’s Why Goldman Sachs Sees A 166% Upside
CRVSApril 17, 2026
Stocktwits
CRVS Stock Surges 10%, Hits 50-DMA For First Time In A Month – Here’s Why Goldman Sachs Sees A 166% Upside
CRVS

MarketBeat
Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026
CRVSFebruary 2, 2026
MarketBeat
Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026
CRVS

Zacks Investment Research
Corvus Pharmaceuticals Stock Rallies 209% in a Month: Here's Why
CRVSJanuary 27, 2026
Zacks Investment Research
Corvus Pharmaceuticals Stock Rallies 209% in a Month: Here's Why
CRVS

Zacks Investment Research
Corvus Pharmaceuticals (CRVS) Is Up 211.80% in One Week: What You Should Know
CRVSJanuary 27, 2026
Zacks Investment Research
Corvus Pharmaceuticals (CRVS) Is Up 211.80% in One Week: What You Should Know
CRVS

Zacks Investment Research
Wall Street Analysts Think Corvus (CRVS) Could Surge 25.29%: Read This Before Placing a Bet
CRVSJanuary 27, 2026
Zacks Investment Research
Wall Street Analysts Think Corvus (CRVS) Could Surge 25.29%: Read This Before Placing a Bet
CRVS

Stocktwits
CRVS Stock Surges Pre-Market After Corvus Expands Equity Raise To $175 Million
CRVSJanuary 22, 2026
Stocktwits
CRVS Stock Surges Pre-Market After Corvus Expands Equity Raise To $175 Million
CRVS

Stocktwits
Dow, Nasdaq, S&P 500 Futures Tick Higher After Wall Street’s Worst Day In 3 Months: Why NFLX, AAPL, CRVS, GME, UAL Are In Focus Today
CRVSJanuary 21, 2026
Stocktwits
Dow, Nasdaq, S&P 500 Futures Tick Higher After Wall Street’s Worst Day In 3 Months: Why NFLX, AAPL, CRVS, GME, UAL Are In Focus Today
CRVS

Stocktwits
Corvus Pharma Stock Dips Over 6% After-Hours Following Best Day Ever — What Went Wrong?
CRVSJanuary 21, 2026
Stocktwits
Corvus Pharma Stock Dips Over 6% After-Hours Following Best Day Ever — What Went Wrong?
CRVS
About Corvus Pharmaceuticals, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees37
CEODr. Richard A. Miller M.D.
IPO DateMar 23, 2016
HeadquartersSouth San Francisco, CA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Richard A. Miller M.D. | Co-Founder, President, CEO & Chairman of the Board | 1951 |
| Mr. Leiv Lea | Chief Financial Officer | 1954 |
| Dr. Peter A. Thompson FACP, M.D. | Co-Founder & Independent Director | 1960 |
| Dr. William Benton Jones Ph.D. | Senior Vice President of Pharmaceutical Development | 1966 |
| Mr. Jeffrey S. Arcara | Senior VP & Chief Business Officer | 1969 |
Fundamentals
Valuation
Price-to-book value4.60
PEG ratio0.00
Profitability
Return on Equity-35.00%
Return on Assets-33.00%
EBITDA$-64.13M
Trading
Average volume1,040,459
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 58.15
- MACD 12/26/9
- -0.03
- EMA 9 of MACD
- -0.27
- MACD histogram
- 0.25
- SMA 50
- $11.33
- Price above SMA 50
- EMA 50
- $11.28
- Price above EMA 50
- SMA 200
- $14.09
- Price below SMA 200
- EMA 200
- $12.70
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -7.8 | -26.3 | ||||||||||
| 2022 | -27.4 | -5.3 | -3.5 | -26.0 | -24.3 | +1.0 | -12.9 | +9.1 | -10.9 | +6.1 | +8.1 | -12.4 |
| 2023 | -5.7 | -12.0 | +26.4 | +8.0 | +173.9 | -29.3 | +0.0 | -5.4 | -31.5 | -19.9 | +29.7 | +9.3 |
| 2024 | +13.6 | +5.2 | -18.3 | -16.7 | +34.2 | -17.6 | +38.9 | +49.8 | +30.7 | +73.7 | -0.1 | -35.2 |
| 2025 | -1.3 | -20.3 | -19.5 | +13.2 | +7.4 | -0.7 | +8.0 | +40.0 | +30.0 | +10.7 | +19.4 | -9.5 |
| 2026 | +182.8 | -13.0 | -18.2 | +5.3 | -19.7 | +23.7 | -10.2 | +5.0 | -19.3 | -8.2 | +18.2 |
Compare stocks
Market cap
$967.53M
-
-
-
Price / Earnings ratio
-14.90
-
-
-
Price / Sales ratio
-
-
-
Dividend yield
0.00%
-
-
-
Average volume
1,040,459
-
-
-
Earnings per share
$-0.71
-
-
-



